What is new? • Few small population/rare disease trials are using Bayesian methods and those that don't are ending up under sized and underpowered. • Researchers in rare disease and small population trials should be striving to use Bayesian methods where possible or follow recommendations suggested by Parmar et al. (2016) Abstract Objective : Frequentist trials in Rare disease/small population trials often require unfeasibly large sample size to detect minimum clinically important differences.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Alexina J. Mason
Flexible Bayesian longitudinal models for cost‐effectiveness analyses with informative missing data
Abstract Cost-effectiveness analyses (CEA) are recommended to include sensitivity analyses which make a range of contextually plausible assumptions about missing data. However, with longitudinal data on, for example, patients' health-related quality of life (HRQoL), the missingness patterns can be complicated because data are often missing both at specific timepoints (interim missingness) and following loss to follow-up.
A framework for extending trial design to facilitate missing data sensitivity analyses
Abstract Background Missing data are an inevitable challenge in Randomised Controlled Trials (RCTs), particularly those with Patient Reported Outcome Measures. Methodological guidance suggests that to avoid incorrect conclusions, studies should undertake sensitivity analyses which recognise that data may be ‘missing not at random’ (MNAR). A recommended approach is to elicit expert opinion about the likely outcome differences for those with missing versus observed data.
Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension
[Skip to Content Landing] Original Investigation Caring for the Critically Ill Patient February 12, 2020 JAMA. 2020;323(10):938-949. doi:10.1001/jama.2020.0930 Key Points Question What is the effect on mortality at 90 days of reducing the exposure to vasopressors through permissive hypotension (mean arterial pressure target of 60-65 mm Hg) in intensive care unit (ICU) patients aged 65 years or older receiving vasopressors for vasodilatory hypotension?
Are large randomised controlled trials in severe sepsis and septic shock statistically disadvantaged by repeated inadvertent underestimates of required sample size?
The mortality from severe sepsis and septic shock has fallen demonstrably over the last few years.1 Despite this, many large interventional trials in critical care, encompassing both novel therapeutics and optimised treatment strategies, have failed to confirm improved effectiveness of interventions in comparison with placebo or best routine care. Occasionally, the promise hinted at by small phase II efficacy trials has not been confirmed in larger phase III effectiveness trials.
A Bayesian framework for health economic evaluation in studies with missing data
Health economics studies with missing data are increasingly using approaches such as multiple imputation that assume that the data are “missing at random.” This assumption is often questionable, as—even given the observed data—the probability that data are missing may reflect the true, unobserved outcomes, such as the patients' true health status.
PharmacoEconomics - Open, Volume 1, Issue 2 - Springer
Volume 1, Issue 2, June 2017 ISSN: 2509-4262 (Print) 2509-4254 (Online) In this issue (8 articles)
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Alexina J.
Contact Alexina J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack